1-3 of 3
Shelley Simon
Close
Sort by
Journal Articles

Factors Associated with Refractoriness or Relapse after Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies: Phase 2 First-in-India Industry (IMAGINE) Study

Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Pankaj Malhotra, Akshatha Nayak, Pooja Mallya, Ravi Joshi, Revathy Raj, Rameez Ahamed, Charanpreet Singh, Sudarshan Chougule, Deepak MB, Lakshman Vaidhyanathan, Man Updesh Singh Sachdeva, Karthik GA, Sunil HV, Jayaraj Govindaraj, Shelley Simon, Rajender Kumar Basher, Nalini Raju, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Anil Kamat
Journal: Blood
Blood (2023) 142 (Supplement 1): 6879.
https://doi.org/10.1182/blood-2023-181112
Published: 2023
Journal Articles

Primary Analysis of Varnimcabtagene Autoleucel (IMN-003A) in Phase 2 Study (IMAGINE), a First-in-India Industry CD19-Directed CAR-T Cell Therapy for Patients with Relapsed Refractory B Cell Malignancies

Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Pankaj Malhotra, Akshatha Nayak, Pooja Mallya, Ravi Joshi, Revathy Raj, Rameez Ahamed, Charanpreet Singh, Deepak MB, Sudarshan Chougule, Lakshman Vaidhyanathan, Man Updesh Singh Sachdeva, Karthik GA, Sunil HV, Jayaraj Govindaraj, Shelley Simon, Rajender Kumar Basher, Sudeshna Dhar, Arun Kumar MG, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Anil Kamat
Journal: Blood
Blood (2023) 142 (Supplement 1): 2104.
https://doi.org/10.1182/blood-2023-179424
Published: 2023
Journal Articles

Reinfusion of Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies Is Feasible with Sustained Responses

Sharat Damodar, Raja Thirumalairaj, Akshatha Nayak, Shilpa Prabhu, Rameez Ahamed, Deepak MB, Sudarshan Chougule, Lakshman Vaidhyanathan, Karthik GA, Sunil HV, Shelley Simon, Jayaraj Govindaraj, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Anil Kamat
Journal: Blood
Blood (2023) 142 (Supplement 1): 6858.
https://doi.org/10.1182/blood-2023-181106
Published: 2023